EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Population Effectiveness of Dolutegravir Implementation in Uganda: A Prospective Observational Cohort Study (DISCO), 48-Week Results

Suzanne M McCluskey iD, Winnie R Muyindike iD, Victoria Nanfuka, Daniel Omoding iD, Nimusiima Komukama, Ian T Barigye, Lydia Kansiime, Justus Tumusiime, Taing N Aung iD, Ashley Stuckwisch, Bethany Hedt-Gauthier iD, Vincent C Marconi iD und 6 weitere

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiae260 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Suzanne M McCluskey und 17 weiteren Autor:innen. Beteiligte Einrichtung: Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Pyridones, Heterocyclic Compounds, 3-Ring, HIV Infections, Oxazines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Wellcome, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tenofovir/lamivudine/dolutegravir (TLD) is the preferred first-line antiretroviral therapy (ART) regimen for people with HIV (PWH), including those who were previously virologically suppressed on nonnucleoside reverse transcriptase inhibitors (NNRTIs). We sought to estimate the real-world effectiveness of the TLD transition in Ugandan public-sector clinics.

Methods

We conducted a prospective cohort study of PWH aged ≥18 years who were transitioned from NNRTI-based ART to TLD. Study visits were conducted on the day of TLD transition and 24 and 48 weeks later. The primary end point was viral suppression (<200 copies/mL) at 48 weeks. We collected blood for retrospective viral load (VL) assessment and conducted genotypic resistance tests for specimens with VL >500 copies/mL.

Results

We enrolled 500 participants (median age 47 years; 41% women). At 48 weeks after TLD transition, 94% of participants were in care with a VL <200 copies/mL (n = 469/500); 2% (n = 11/500) were lost from care or died; and only 2% (n = 9/500) had a VL >500 copies/mL. No incident resistance to DTG was identified. Few participants (2%, n = 9/500) discontinued TLD due to adverse events.

Conclusions

High rates of viral suppression, high tolerability, and lack of emergent drug resistance support use of TLD as the preferred first-line regimen in the region. Clinical Trials Registration NCT04066036.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridonesHeterocyclic Compounds, 3-RingHIV InfectionsOxazinesPiperazinesViral LoadAnti-HIV AgentsHumansFemaleUgandaMaleProspective StudiesMiddle AgedAdultLamivudineTenofovirHIV-1Treatment OutcomeDrug Resistance, ViralYoung AdultDolutegravir

Stichwörter der Autor:innen

HIV drug resistanceTLDantiretroviral therapydolutegravirsub-Saharan Africa

Substanzen

PyridonesHeterocyclic Compounds, 3-RingOxazinesPiperazinesAnti-HIV AgentsLamivudineTenofovirDolutegravir

Autor:innen und Institutionen

  • Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Mbarara University of Science and Technology, Mbarara, Uganda.
  • Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Emory University School of Medicine and Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.

ORCID-Profile: Suzanne M McCluskey, Winnie R Muyindike, Daniel Omoding, Taing N Aung, Bethany Hedt-Gauthier, Vincent C Marconi, Deenan Pillay, Richard Lessells, Ravindra K Gupta, Mark J Siedner

Förderung

  • NIAID NIH HHS
  • Wellcome
  • NIH HHS
  • Emory Center for AIDS Research
  • Wellcome Trust
  • NHLBI NIH HHS
  • National Institutes of Health

Zitieren

APA

McCluskey, S. M., Muyindike, W. R., Nanfuka, V., Omoding, D., Komukama, N., Barigye, I. T., Kansiime, L., Tumusiime, J., Aung, T. N., Stuckwisch, A., Hedt-Gauthier, B., Marconi, V. C., Moosa, M. S., Pillay, D., Giandhari, J., Lessells, R., Gupta, R. K., & Siedner, M. J. (2024). Population Effectiveness of Dolutegravir Implementation in Uganda: A Prospective Observational Cohort Study (DISCO), 48-Week Results. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae260

Vancouver

McCluskey SM, Muyindike WR, Nanfuka V, Omoding D, Komukama N, Barigye IT, et al. Population Effectiveness of Dolutegravir Implementation in Uganda: A Prospective Observational Cohort Study (DISCO), 48-Week Results. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae260

BibTeX
@article{McCluskey2024,
  author = {McCluskey, Suzanne M and Muyindike, Winnie R and Nanfuka, Victoria and Omoding, Daniel and Komukama, Nimusiima and Barigye, Ian T and Kansiime, Lydia and Tumusiime, Justus and Aung, Taing N and Stuckwisch, Ashley and Hedt-Gauthier, Bethany and Marconi, Vincent C and Moosa, Mahomed-Yunus S and Pillay, Deenan and Giandhari, Jennifer and Lessells, Richard and Gupta, Ravindra K and Siedner, Mark J},
  title = {Population Effectiveness of Dolutegravir Implementation in Uganda: A Prospective Observational Cohort Study (DISCO), 48-Week Results},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiae260}
}
Kostenlos starten →